Cardiac function during iron chelation therapy in adult non- thalassaemic patients with transfusional iron overload

European Journal of Haematology

Volumn 59, Issue 4, 1997, Pages 221-230

  Jensen, P D ^a   Olsen, N ^b   Bagger, J P ^a   Jensen, F T ^a   Christensen, T ^a   Ellegaard, J ^a  

^a AARHUS UNIVERSITY HOSPITAL   (Denmark)

^b Aarhus Kommunehopital ^*  (Denmark)

Author keywords

Cardiac ejection fraction; Desferrioxamine; Iron chelation; MUGA; Transfusional iron overload; Vitamin C

Indexed keywords

ASCORBIC ACID; DEFEROXAMINE;

ADULT; AGED; ARTICLE; BETA THALASSEMIA; BLOOD TRANSFUSION; CLINICAL ARTICLE; DIET SUPPLEMENTATION; ERYTHROPOIESIS; FEMALE; HEART FUNCTION; HEART LEFT VENTRICLE EJECTION FRACTION; HUMAN; IRON BLOOD LEVEL; IRON CHELATION; IRON OVERLOAD; MALE; PRIORITY JOURNAL; SURVIVAL RATE;

EID: 9844258340     PISSN: 09024441     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1600-0609.1997.tb00981.x     Document Type: Article

References (33)

1. WOLFE L, OLIVIERI N, SALLAN D, et al. Prevention of cardiac disease by subcutaneous desferrioxamine in patients with thalassemia major. N Engl J Med 1985: 312: 1600-1603.
2. FREEMAN AP, GILES RW, BERDOUKAS VA, et al. Sustained normalization of cardiac function by chelation therapy in thalassaemia major. Clin Lab Med 1989: 11: 299-307.
3. MARCUS RE, DAVIES SC, BANTOCK HM, et al. Desferrioxamine to improve cardiac function in iron-overloaded patients with thalassaemia major. Lancet 1984: i: 392-393.
4. HYMAN CB, AGRESS CL, RODRIGUEZ-FUNES R. Continued subcutaneous and high-dose intravenous desferrioxamine in patients with thalassaemia major. N Engl J Med 1985: 312: 1600-1603.
5. RAHKO PS, SALERNI R, URETSKY, BF. Successful reversal by chelation therapy of congestive cardiomyopathy due to iron overload. J Am Coll Cardiol 1986: 8: 436-440.
6. SCHAFER AI, CHERON RG, DLUHY R, et al. Clinical consequences of acquired transfusional iron overload in adults. N Engl J Med 1981: 304: 319-324.
7. SCHAFER AI, RABINOWE S, LE BOFF MS, et al. Long-term efficacy of desferrioxamine iron chelation therapy in adults with acquired transfusional iron overload. Arch Int Med 1985: 145: 1217-1221.
8. JENSEN PD, JENSEN IM, ELLEGAARD J. Desferrioxamine treatment reduces blood transfusion requirements in patients with myelodysplastic syndrome. Br J Haematol 1992: 80: 121-124.
9. JENSEN PD, HEICKENDORFF L, BENDIX-HANSEN K, et al. The effect of iron chelation on haematopoiesis in MDS patients with transfusional iron overload. Br J Haematol 1996: 94: 288-299.
10. POOTRAKUL P, KITCHAROEN K, YANSUKON P et al. The effect of erythroid hyperplasia on iron balance. Blood 1988: 71: 1124-1129.
11. HENRY W. Echocardiographic evaluation of the heart in thalassemia major. Ann Intern Med 1979: 91: 892-894.
12. NIENHUIS AW. Vitamin C and iron. N Engl J Med 1981: 304: 170-171.
13. BENNETT JM, CATOVSKY D, DANIEL MT, et al. Proposals for the classification of the myelodysplastic syndromes. Br J Haematol 1982: 51: 189-199.
14. PIPPARD MJ. Desferrioxamine-induced iron excretion in humans. Baillière's Clinical Haematology 1989: 4: 323-343.
15. GORIS ML, DASPIT SG, MCLAUGHLIN P, et al. Interpolative background subtraction. J Nucl Med 1976: 17: 44-47.
16. JENSEN FT, LUND O, ERLANDSEN M. Reliability of three computer methods in the analysis of ECG-gated radionuclide left ventriculography: interrecording, interobserver and intraobserver variability. Angiology 1991: 42: 866-877.
17. LUND O, RASSMUSSEN K, JENSEN FT, et al. Left ventricular ejection fraction determined with the nuclear stethoscope, gamma camera and contrast ventriculography. Nucl Med Commun 1986: 7: 337-348.
18. LAUBER, K. Bestimmung von Serumeisen und Eisenbindungskapazität ohne Enteiweißung. Z Klin Chem 1965: 3: 96-99.
19. JOHNSTON DL, RICE L, VICK GW, et al. Assessment of tissue iron overload by nuclear magnetic resonance imaging. Am J Med 1989: 87: 40-47.
20. JENSEN PD, JENSEN FT, CHRISTENSEN T, et al. Non-invasive assessment of tissue iron overload in the liver by magnetic resonance imaging. Br J Haematol 1994: 87: 171-184.
21. LEON MB, BORER JS, BACHARACH SL, et al. Detection of early cardiac dysfunction in patients with severe betathalassemia and chronic overload. N Engl J Med 1979: 301: 1143-1148.
22. JENSEN PD, JENSEN FT, CHRISTENSEN T, et al. Evaluation of transfusional iron overload and iron chelation therapy by magnetic resonance imaging of the liver and determination of serum ferritin. Br J Haematol 1995: 89: 880-889.
23. MARCUS RE, HUEHNS ER. Transfusional iron overload. Clin Lab Haematol 1985: 7: 195-212.
24. CAZZOLA M, DE STEFANO R PONCHIO L, et al. Relationship between transfusion regimen and suppression of erythropoiesis in b-thalassaemia. Br J Haematol 1995: 89: 473-478.
25. HALLIDAY CEW, HALLIDAY JW, POWELL LW. The clinical manifestations of chronic iron overload. In: HERSHKO C, ed. Baillière's Clinical Haematology, vol II. London: Baillière Tindall, 1989; 403.
26. BUJA L, ROBERTS WC. Iron in the heart. Etiology and clinical significance. Am J Med 1971: 51: 209-221.
27. LAHTINEN R, KUIKKA J, NOUSIAINEN T, et al. Cardiotoxity of epirubicin and doxorubicin: a double-blind randomized study. Eur J Haematol 1991: 46: 301-305.
28. WAPNICK AA, LYNCH SR, CHARLTON RW, et al. The effect of ascorbic acid deficiency on desferrioxamine-induced urinary iron excretion. Br J Haematol 1969: 17: 563-568.
29. O'BRIEN RT. Ascorbic acid enhancement of desferrioxamine induced urinary iron excretion in thalassemia major. Ann NY Acad Sci 1974: 232: 221-225.
30. PIPPARD MJ, CALLENDER ST, FINCH CA. Ferrioxamine excretion in iron-loaded man. Blood 1982: 60: 288-294.
31. LIVREA MA, TESORIERE L, PINTAUDI AM, et al. Oxidative stress and antioxidant status in β-thalassaemia major: iron overload and depletion of lipid-soluble antioxidants. Blood 1996: 88: 3608-3614.
32. DOROSHOW JH, LOCKER, GY, MYERS CE. Enzymatic def ence of mouse heart against reactive oxygen metabolites. Alterations produced by doxorubicin. J Clin Invest 1980: 65: 128-135.
33. HOFFBRAND AV, WONKE B. Results of long-term subcutaneous DFO therapy. In: HERSHKO C, ed. Baillière's Clinical Haematology, vol II. London: Baillière Tindall, 1989: 345.